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Summary
No information is available on prevalence of primary hy-
poparathyroidism in the general population. This report de-
scribes the establishment and development of a national epi-
demiological survey on primary hypoparathyroidism in Italy
through a Register, named RIIP. The services offered to the re-
ferring Centers and the data collected through the Italian Reg-
ister are detailed and discussed. This example offers a possi-
bility that others could follow, allowing the construction of
databases necessary for epidemiological studies and for the
design of clinical trials in such rare diseases. 
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Introduction
Calcium is an important bioinorganic ion performing a variety of
intra- and extra-cellular functions and playing an important role
in maintaining normal physiologic processes. It is also an im-
portant component or co-factor required for the proper function-
ing of coagulation factors and adhesion molecules. 
Homeostasis of calcium and phosphorus is maintained by a
combined activity of the calciotropic hormones: parathyroid
hormone (PTH), Vitamin D [25 OH2D3 and 1-25 (OH)2D3], and
calcitonin (CT). PTH, the product of the parathyroid glands,
regulates serum calcium concentrations and bone metabolism.
In turn serum calcium concentrations regulate PTH secretion
by means of a calcium-sensing receptor (CaSR) on the surface
of parathyroid cells. 
The term of primary hypoparathyroidism refers to a group of in-
herited disorders in which the relative or absolute deficiency of
PTH leads to hypocalcemia and hyperphosphatemia (Table I).
These disorders may be caused by developmental defects in
the parathyroid glands, by autoimmune endocrinopathies, by
defects in PTH synthesis, by impaired regulation of PTH secre-
tion, and by defective PTH action. The latter forms termed
pseudo-hypoparathyroidism are unique in that PTH secretion is
increased rather than deficient. 
A cause of hypoparathyroidism is represented by an anom-
alous development of parathyroid glands. The disease called
DiGeorge syndrome can be sporadic or familiarly transmitted
as autosomal dominant trait (1, 2).
The polyglandular disorder called autoimmune polyglandular
syndrome type 1 (APS 1) is characterized by autoimmune Ad-
dison’s disease, moniliasis, and hypoparathyroidism. A gene
encoding for a putative regulator of transcription featuring two
PHD-type zinc-finger motifs (A IR E : Au t oImmune Re g u l a t o r )
has been discovered as the primary cause of APS 1 (3). 
Mutations of the pr e p r o - P T H gene are commonly involved in
the pathogenesis of familial isolated hypoparathyroidism trans-
mitted in autosomal mode. Familial hypoparathyroidism can al-
so be X-linked (4). In other cases, linkage of hypocalcemia to
the locus of the CaSR gene (3q21-24) has been demonstrated
in some forms of familial hypoparathyroidism (5, 6). Hy-
p parathyroidism has been also reported to occur in two disor-
ders associated with mitochondrial dysfunctions (7, 8).
Clinical Cases in Mineral and Bone Metabolism 2004; 1(2): 157-161 157
The Italian Register of primary hypoparathyroidism
Article
Table I - Categories of primary hypoparathyroidism.
Causes Diagnosis
Developmental defects in the parathyroid glands • DiGeorge syndrome
• Autosomal recessive hypoparathyroidism 
• Kenney-Caffey syndrome
• Mitochondrial neuromyopathy
Autoimmune disorders • APS 1
Defects of the parathyroid hormone molecule • Mutations of PTH gene
Defective regulation of parathyroid hormone • Activating mutation of the CaSR gene
Defect of the type 1 PTH receptor • Jansen’s chondrodystrophy
• Blomstrand’s chondrodystrophy
Defect of the stimulatory Gsa subunit • PHP-Ia and PHP-Ib
• PPHP
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Mutations of the Gsa subunit gene (GNAS1) (20q13-11) have
been identified in patients with pseudohypoparathyroidism type
Ia (PHP-Ia) and with pseudo-pseudohypoparathyroidism
(PPHP). PHP is an autosomal dominant disorder characterized
by a typical phenotype (9, 10).
Italian Register of Primary Hypoparathyroidism 
In 1996 an Italian Register of Primary Hypoparathyroidism was
created in Florence and named RIIP (Registro It a l i a n o
Ipoparatiroidismo Primitivo: www.dmi.unifi.it/ipopara/default.htm).
It is a passive register and its Central Secretariat has been es-
tablished in Florence. RIIP collects clinical records both on spo-
radic and familial cases of primary hypoparathyroidism. Informa-
tion was obtained from Italian endocrine, neurological and pedi-
atric Centers through the compilation of a simple form, that in-
cludes the identification code of the patient, the date of birth, the
diagnosis of the type of hypoparathyroidism, the presence of
other associated diseases (typical or not), the data on organ and
non-organ antibodies, the results of PTH infusion and genetic
tests. Each subject is requested to give informed consent and at
any time the patient can ask to obtain his/her clinical data delet-
ed from the official file. The form (available on request) has been
arranged to be sent by fax and e-mail (Table II).
Goals of the RIIP
The primary goal of the RIIP is the collection of clinical data in
order to elaborate epidemiological results on incidence, preva-
lence and geographical clustering of primary hypoparathy-
roidism in Italy. The Register supports also the genetic test for
Centers not equipped for molecular diagnostic procedures. The
collection of these data will make possible a nation-wide survey
of the problem and the definition of the prevalence of typical
and atypical lesions both in affected patients and their rela-
tives. Through this approach the incidence and prevalence of
the various disorders in Italy will be compared to what de-
scribed in other countries. Finally, the possibility of collecting
kindreds affected by rare disorders will make available large
patient cohorts necessary in clinical trials designed to recog-
nize therapeutical interventions suitable to a given disorder. 
Several genes are involved in the pathogenesis of hypocalcemic
disorders due to parathyroid tissue/PTH response dysfunction.
The mutational analysis of G N A S 1 gene, the parathyroid hor-
mone (P T H) gene, the PTH/PTHrP receptor (PT H / P T H r P r)
gene, the C a S R gene, the human orthologue gene of the
Drosophila glial cells missing gene dGCM (G C M B) gene, the
GATA3 transcription factor (G A T A 3) gene and the AI R E gene in
patients recorded at the RIIP should make possible to identify
mutations that have been described in the literature and eventu-
al new mutations responsible for the various (typical or not-typi-
cal) forms of primary hypoparathyroidism. In addition, microar-
rays will make possible to study the expression profile and hap-
lotypes of genes involved in the pathogenesis of hypocalcemic
di orders through the construction of a “gene cassette” useful to
clarify the metabolic pathways underlying the hypocalcemic dys-
functions. Future advances will be important for the discovery
both of novel genetic markers and of the pathogenesis of these
disorders, making possible to identify early latent states of
hypocalcemia and to create guidelines for diagnostic and clinical
management of hypoparathyroid patients in Italy.
Results of the RIIP
So far 109 hypocalcemic patients have been registered in the
RIIP of Florence. Subjects had an age ranging from 6 to 71
y ars. Both sexes were represented (48 female and 61 males).
There were 14 cases of PHPIa; 8 cases of PHPIb; 8 cases of
PPHP; 57 cases of idiopathic hypoparathyroidism; 2 case of
DiGeorge syndrome; 8 cases of isolated parathyroid agenesis;
9 cases of APS 1; and 3 cases of universal calcinosis (Table
III). The geographical distribution of the patients was the follow-
ing: 51% from the South, 39% from the Center, and 10% form
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Table II - Form for collecting information on patients affected by primary hypoparathyroidism.
Patient’s Surname Date of Type of Associated Organ- Non Organ- Test for Genetic
code # and name birth hypopara- diseases** specific specific pseudohypo- diagnosis
thyroidism* antibodies antibodies parathyroidism
diagnosis***
* A) Hypoparathyroidism 1) Parathyroid agenesis or 2) DiGeorge syndrome; B) Autoimmune hypoparathyroidism 1) Isolated or  2) Polyglandular autoimmune
syndrome type I; C) Hypoparathyroidism 1) Deficient parathyroid hormone secretion; D) Pseudohypoparathyroidism; E) Pseudo-pseudohypoparathyroidism. 
** A) Insulin dependent diabetes; B) Hypogonadism; C) Adrenal insufficiency; D) Pernicious anemia; E) Alopecia; F) Candidiasis; G) Hypothyroidism.
*** PTH test.
Table III - Subjects registered at the RIIP.
Disease Number
Isolated parathyroid agenesis 18
DiGeorge syndrome 12
Idiopathic hypoparathyroidism 57
APS 1 19
PHP-Ia 14
PHP-Ib 18
PPHP 18
Universal calcinosis 13
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the North of Italy (Fig. 1).
Thirty-nine patients (10 women and 29 men) with a mean age
40±22.4 SEM years (range 7-66) underwent genetic test to
evaluate the presence of G N A S 1 gene mutations. For 4 of
them, blood samples for genetic analysis from relatives were
made available. 
Developmental status of the patients was appropriate. The entire
cohort of patients was biochemically characterized by serum
evaluation of calcium, phosphorus, magnesium, alkaline phos-
phatase, PTH, vitamin D (25 OH2D3 and 1-25 OH2D3), and or-
gan- and non-organ specific antibodies. Thyroid function was
evaluated by measurement of serum TSH, fT3 and fT4. A sample
of urine was collected in order to evaluate the excretion of calci-
um, phosphorus, magnesium deoxypiridinoline and cyclic AMP.
In addition, routine exams were performed in all patients. Lumbar
spine BMD (LS-BMD) was also measured by DEXA (Hologic
QDR 4500). Electrorcardiogram, electromyography, ocular in-
spection and skull X-ray and/or CT were performed in all patients. 
A new T>C polymorphic site of the GNAS1 gene was found in
7 patients and 4 relatives from different families indicated by A,
B, C, D1, D2, D3, E1, F1, F2, G1, and G2 and it was not asso-
ciated with modifications of restriction endonuclease recogni-
tion sequences (Table IV). The clinical characteristics of pa-
tients and of their first-degree relatives are summarized in
Table IV. A patient affected (D1) and his sons (D2 and D3)
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Table IV - Clinical and biochemical data of the hypocalcemic patients with GNAS1 gene mutations.
Code Sex Age S-Ca UrCa s-P PTH TSH Diagnosis and Imaging GNAS1 gene
# (Yr) (8.5-10.5 (100-300 (2.8-4.5 (10-60 (0.25-3.5 clinical signs mutation
mg/dL)* mg/24h) mg/dL) ng/mL) mU/mL)
A1 F 65 6,8 362 4.8 26 <0.05 Late idiopathic hypocalcemic crisis IC Heterozygous
hyperthyroidism intron 5 T>C variant 
nuc.433–18
B1 F 59 3,8 99 Late idiopathic hypocalcemic crisis IC Heterozygous
intron 5 T>C variant 
nuc.433–18
C1 M 66 7.7 244 3.8 45 NA Late idiopathic hypocalcemic crisis IC Heterozygous 
intron 5 T>C variant 
nuc.433–18
D1 M 47 5.9 235 4.68 137 3.6 PHP Ib, Subclinical hypothyroidism IC Heterozygous
cataract, Br intron 5 T>C variant 
nuc.433–18
D2 (S) M 15 9.8 200 4.7 42.3 NA N NA Heterozygous 
intron 5 T>C variant 
nuc.433–18
+
Heterozygous
exon 13 C>T variant
c.1113
D3 (S) M 17 9.7 230 4.5 58 NA N NA Heterozygous 
intron 5 T>C variant 
nuc.433–18
D4 (W) F 45 10.1 245 3.5 62 NA N NA NP
E1 M 48 NA Late idiopathic hypocalcemic crisis Heterozygous 
intron 5 T>C variant 
nuc.433–18
F1 F 7 7.9 288 4.5 143 6.64 PHP Ia, Br, Ob, RF, SC SM Heterozygous 
intron 5 T>C variant 
nuc.433–18
Figure 1 - Geographical distribution of the patients recorded at the RIIP.
Of the total subjects registered at the RIIP 51% were from the South,
39% from the Center, and 10% form the North of Italy.
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showed the heterozygous T>C mutation and no mutations
were found in the mother (D4). Patient D2 had a polymorphism
at the exon 13 together with the T>C polymorphism at the in-
tron 5 (11). In addition, 13 patients had a polymorphism at the
exon 5 of the GNAS1 gene previously described by Miric et al.
(12). Two subjects were homozygous (Table IV). The clinical
characteristic of 4 of the patients was available and reported in
Table IV (subjects D2, L1, M1, M2, and N1). One patient (H1)
affected by PHP-Ia had a missense mutation of the G N A S 1
gene, characterized by Pro® Leu at the codon 115 in the exon
5, previously described by de Sanctis et al. (13).
Three patients affected by APS 1 and their first-degree rela-
tives underwent genetic test to evaluate the presence of AIRE
gene mutations. Table V shows the characteristics of these pa-
tients and relatives. The probands A1 and A2 had a homozy-
gous mutation Thr® Met at the codon 16 in the exon 1 and a
heterozygous mutation Prol® Leu at the codon 252 in the exon
6 already described in the literature (14, 15). The mother (A3)
had the heterozygous mutation Thr® Met at the codon 16 in
the exon 1 and the father (A4) had both heterozygous mutation
Thr® Met at the codon 16 in the exon 1 and the heterozygous
mutation Prol® Leu at the codon 252 in the exon 6. 
The B1 proband had a homozygous Arg® Stop Codon muta-
tion in the exon 5 previously described by Scott et al. (16). The
mother (B2), the father (B3), and the brother (B4) had the
same heterozygous mutation. 
Conclusions
The recognition of the pathogenetic basis of hypocalcemic dis-
orders is important for patient care, providing important clues
for management, as subjects with activating C a S R m u t a t i o n s
cannot be treated with vitamin D but would benefit most from
PTH injections (17). Therapy of hypoparathyroid patients is not
a primary outcome of the RIIP, however, the collection of pa-
tient populations clinically and genetically characterized, repre-
sents the necessary basis for the recognition of selected popu-
lations for clinical trials. Finally, a careful genetic study of these
patients will be useful in: a) precocious diagnosis of patients af-
fected by a hypocalcemic disorder; b) prevention of complica-
tions due to chronic hypocalcemia; and c) early treatment of
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Table IV - continued
Code Sex Age S-Ca UrCa s-P PTH TSH Diagnosis and Imaging GNAS1 gene
# (Yr) (8.5-10.5 (100-300 (2.8-4.5 (10-60 (0.25-3.5 clinical signs mutation
mg/dL)* mg/24h) mg/dL) ng/mL) mU/mL)
F2 (M) F 36 10 160 3.9 40 NA Br NA Heterozygous 
intron 5 T>C variant 
nuc.433–18
F3 (F) M 50 9.8 185 3.5 65 NA N NA NP
G1 M 17 8.2 180 4.2 56 2.9 Br, osteopenia, NA Heterozygous 
hyperprolactinemia, SM intron 5 T>C variant 
nuc.433–18
G2 (B) M 21 9.6 213 3.9 57 NA N NA Heterozygous 
intron 5 T>C variant 
nuc.433–18
G3 (M) F 62 9.5 228 2.9 60 NA N NA NP
H1 F 15 8.1 282 4.6 157 7.9 PHP Ia, Br, Ob, RF NA Heterozygous
exon 5 Pro® Leu 
c. 115 
L1 F 56 8.4 300 3.5 48 NA Late idiopathic hypocalcemic crisis NA Homozygous 
exon 13 C>T variant
c. 1113
M1 F 48 7.9 340 4.7 6 2.8 Hypoparathyroidism NA Heterozygous
exon 13 C>T variant 
c.1113 
M2 (F) M 78 8.2 380 4 12 NA Hypoparathyroidism NA Homozygous
exon 13 C>T variant 
c.1113 
M3 (M) F 76 9 267 3.4 45 NA N NA NP
N1 F 56 8.5 280 4 12 NA Late idiopathic hypocalcemic crisis Heterozygous
exon 13 C>T variant 
c.1113
# Proband: bold characters
* Serum calcium levels were corrected for albumin concentration.
Abbreviations: F: Female; M: Male; (F): Father; (M): Mother; (S): Son; (W): Wife.
In alphabetic order: Br: Brachidactyly; IC: Intracranic Calcification; N: Normal; NA: Not Available; Ob: Obesity; NP: Not Polymorphic; PHP: Pseudohypoparathy-
roidism; RF: Round Face; SC: Subcutaneous Calcification; SM: Shortening of Metacarpals.
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associated disorders. 
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Table V - Clinical characteristics of the subjects with AIRE gene mutations.
Code Sex Age (Yr) Diagnosis AIRE
# gene mutation
A1 F 10 APS 1 Homozygous exon 1 Thr® Met c.16 
+
Heterozygous exon 6 Prol® Leu c. 252
A2 M 12 APS 1 Homozygous exon 1 Thr® Met c.16 
+
Heterozygous exon 6 Prol® Leu c. 252
A3 (M) F 56 N Heterozygous exon 1 Thr® Met c.16
A4 (F) M 60 N Heterozygous exon 1 Thr® Met c.16 
+
Heterozygous exon 6 Prol® Leu c. 252
B1 F 15 APS 1 Homozygous exon 5 Arg® Stop Codon 
B2 (M) F 59 N Heterozygous exon 5 Arg® Stop Codon 
B3 (F) M 64 N Heterozygous exon 5 Arg® Stop Codon 
B4 (B) M 17 N Heterozygous exon 5 Arg® Stop Codon
# Proband: bold characters
Abbreviations: F: Female; M: Male; (F): Father; (M): Mother; (B): Brother.
In alphabetic order: APS 1: Autoimmune Polyglandular Syndrome Type I; N: Normal.
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